Although Waldenstrom Macroglobulinemia (WM) typically affects the elderly, no studies so far have specifically addressed the impact of age, comorbidities, ECOG-PS and concomitant medications on treatment outcomes. Data on WM receiving ibrutinib outside of clinical trials are sparse, showing 18-20% and 8-35% of pts requiring permanent dose reduction (PDR) and toxicity-related definitive treatment discontinuation (Tox-DTD). Furthermore, the impact of polypharmacy and drug interference while on ibrutinib is still unexplored. The aim of this study is to evaluate which fitness parameters are significant for treatment outcome and management in patients with WM receiving ibrutinib in clinical practice
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
Rita, Rizzi;
2022-01-01
Abstract
Although Waldenstrom Macroglobulinemia (WM) typically affects the elderly, no studies so far have specifically addressed the impact of age, comorbidities, ECOG-PS and concomitant medications on treatment outcomes. Data on WM receiving ibrutinib outside of clinical trials are sparse, showing 18-20% and 8-35% of pts requiring permanent dose reduction (PDR) and toxicity-related definitive treatment discontinuation (Tox-DTD). Furthermore, the impact of polypharmacy and drug interference while on ibrutinib is still unexplored. The aim of this study is to evaluate which fitness parameters are significant for treatment outcome and management in patients with WM receiving ibrutinib in clinical practice| File | Dimensione | Formato | |
|---|---|---|---|
|
How age, comorbidities.pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
708.56 kB
Formato
Adobe PDF
|
708.56 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
